Sally J DeNardo

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint A new era for radiolabeled antibodies in cancer?
    S J Denardo
    Molecular Cancer Institute, Hematology Oncology Department, University of California Davis Medical Center, 1508 Alhambra Boulevard, Room 3100, Sacramento, CA 95816, USA
    Curr Opin Immunol 11:563-9. 1999
  2. pmc Hexa-arginine enhanced uptake and residualization of selective high affinity ligands by Raji lymphoma cells
    Rod Balhorn
    University of California, Department of Applied Science, Hertz Hall, Livermore, CA 94551, USA
    Mol Cancer 8:25. 2009
  3. ncbi request reprint Choosing an optimal radioimmunotherapy dose for clinical response
    Sally J DeNardo
    Department of Internal Medicine, Division of Hematology and Oncology, Section of Radiodiagnosis and Therapy, University of California, Davis Medical Center, Sacramento, California 95816, USA
    Cancer 94:1275-86. 2002
  4. ncbi request reprint Development of tumor targeting bioprobes ((111)In-chimeric L6 monoclonal antibody nanoparticles) for alternating magnetic field cancer therapy
    Sally J DeNardo
    University of California, Davis, Sacramento, California, USA
    Clin Cancer Res 11:7087s-7092s. 2005
  5. doi request reprint 111In-LLP2A-DOTA Polyethylene Glycol-Targeting {alpha}4{beta}1 Integrin: Comparative Pharmacokinetics for Imaging and Therapy of Lymphoid Malignancies
    Sally J DeNardo
    Division of Hematology and Oncology, Department of Internal Medicine, UC Davis School of Medicine, Sacramento, California, USA
    J Nucl Med 50:625-34. 2009
  6. ncbi request reprint Enhancement of the therapeutic index: from nonmyeloablative and myeloablative toward pretargeted radioimmunotherapy for metastatic prostate cancer
    Sally J DeNardo
    School of Medicine, University of California Davis, Sacramento, California 95816, USA
    Clin Cancer Res 11:7187s-7194s. 2005
  7. ncbi request reprint Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RIT
    Sally J DeNardo
    University of California Davis School of Medicine, Sacramento, California 95816, USA
    Clin Cancer Res 9:3938S-44S. 2003
  8. ncbi request reprint Combined molecular targeting for cancer therapy: a new paradigm in need of molecular imaging
    Sally J DeNardo
    University of California Davis Medical Center, Sacramento, 95816, USA
    J Nucl Med 47:4-5. 2006
  9. ncbi request reprint Effect of molecular size of pegylated peptide on the pharmacokinetics and tumor targeting in lymphoma-bearing mice
    Sally J DeNardo
    Department of Internal Medicine, University of California Davis Medical Center, Sacramento, California 95816, USA
    Clin Cancer Res 9:3854S-64S. 2003
  10. doi request reprint Development of multivalent radioimmunonanoparticles for cancer imaging and therapy
    Arutselvan Natarajan
    Department of Internal Medicine, University of California Davis, Sacramento, California, USA
    Cancer Biother Radiopharm 23:82-91. 2008

Collaborators

Detail Information

Publications60

  1. ncbi request reprint A new era for radiolabeled antibodies in cancer?
    S J Denardo
    Molecular Cancer Institute, Hematology Oncology Department, University of California Davis Medical Center, 1508 Alhambra Boulevard, Room 3100, Sacramento, CA 95816, USA
    Curr Opin Immunol 11:563-9. 1999
    ..Extended complete remissions and even increased survival have been achieved in lymphoma. Similar results in other cancers seem likely with RIT in combination therapy...
  2. pmc Hexa-arginine enhanced uptake and residualization of selective high affinity ligands by Raji lymphoma cells
    Rod Balhorn
    University of California, Department of Applied Science, Hertz Hall, Livermore, CA 94551, USA
    Mol Cancer 8:25. 2009
    ....
  3. ncbi request reprint Choosing an optimal radioimmunotherapy dose for clinical response
    Sally J DeNardo
    Department of Internal Medicine, Division of Hematology and Oncology, Section of Radiodiagnosis and Therapy, University of California, Davis Medical Center, Sacramento, California 95816, USA
    Cancer 94:1275-86. 2002
    ..Future clinical trial designs, the sophistication of dosimetry, treatment planning, and clinical treatment decisions should all be focused on achieving the best benefit-risk relationship for each patient...
  4. ncbi request reprint Development of tumor targeting bioprobes ((111)In-chimeric L6 monoclonal antibody nanoparticles) for alternating magnetic field cancer therapy
    Sally J DeNardo
    University of California, Davis, Sacramento, California, USA
    Clin Cancer Res 11:7087s-7092s. 2005
    ..Tumor cell radioimmunotargeting of the bioprobes and therapeutic and toxic responses were determined...
  5. doi request reprint 111In-LLP2A-DOTA Polyethylene Glycol-Targeting {alpha}4{beta}1 Integrin: Comparative Pharmacokinetics for Imaging and Therapy of Lymphoid Malignancies
    Sally J DeNardo
    Division of Hematology and Oncology, Department of Internal Medicine, UC Davis School of Medicine, Sacramento, California, USA
    J Nucl Med 50:625-34. 2009
    ..6.2]hexadecane ((64)Cu-LLP2A-CB-TE2A)...
  6. ncbi request reprint Enhancement of the therapeutic index: from nonmyeloablative and myeloablative toward pretargeted radioimmunotherapy for metastatic prostate cancer
    Sally J DeNardo
    School of Medicine, University of California Davis, Sacramento, California 95816, USA
    Clin Cancer Res 11:7187s-7194s. 2005
    ..New strategies that target selected molecular characteristics and result in an effective therapeutic index are needed for metastatic, hormone-refractory prostate cancer...
  7. ncbi request reprint Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RIT
    Sally J DeNardo
    University of California Davis School of Medicine, Sacramento, California 95816, USA
    Clin Cancer Res 9:3938S-44S. 2003
    ....
  8. ncbi request reprint Combined molecular targeting for cancer therapy: a new paradigm in need of molecular imaging
    Sally J DeNardo
    University of California Davis Medical Center, Sacramento, 95816, USA
    J Nucl Med 47:4-5. 2006
  9. ncbi request reprint Effect of molecular size of pegylated peptide on the pharmacokinetics and tumor targeting in lymphoma-bearing mice
    Sally J DeNardo
    Department of Internal Medicine, University of California Davis Medical Center, Sacramento, California 95816, USA
    Clin Cancer Res 9:3854S-64S. 2003
    ....
  10. doi request reprint Development of multivalent radioimmunonanoparticles for cancer imaging and therapy
    Arutselvan Natarajan
    Department of Internal Medicine, University of California Davis, Sacramento, California, USA
    Cancer Biother Radiopharm 23:82-91. 2008
    ..Targeting agents, for example, monoclonal antibodies or peptides, linked to magnetic iron oxide nanoparticles (NP), represent a promising strategy to target cancer cells and hyperthermia...
  11. ncbi request reprint Selective high-affinity ligand antibody mimics for cancer diagnosis and therapy: initial application to lymphoma/leukemia
    Rod Balhorn
    Chemistry, Materials and Life Sciences and Computations, Lawrence Livermore National Laboratory, Livermore, California, 94550, USA
    Clin Cancer Res 13:5621s-5628s. 2007
    ....
  12. ncbi request reprint Preclinical evaluation of cathepsin-degradable peptide linkers for radioimmunoconjugates
    Gerald L DeNardo
    Department of Internal Medicine, School of Medicine, University of California Davis, Sacramento, CA 95816, USA
    Clin Cancer Res 9:3865S-72S. 2003
    ..To assess whether in vitro cathepsin-degradable peptide linkers between the chelated radiometal and the antibody decreased hepatic radiation dose, cumulated activity was used as a surrogate for radiation dose...
  13. ncbi request reprint Characteristics of dimeric (bis) bidentate selective high affinity ligands as HLA-DR10 beta antibody mimics targeting non-Hodgkin's lymphoma
    Gerald L DeNardo
    Radiodiagnosis and Therapy Molecular Cancer Institute, Sacramento, CA 95816, USA
    Int J Oncol 31:729-40. 2007
    ..The concept and methodology are of interest because applicable for targeting most proteins; the SHAL synthetic platform is highly efficient and adaptive...
  14. pmc Nanomolecular HLA-DR10 antibody mimics: A potent system for molecular targeted therapy and imaging
    Gerald L DeNardo
    University of California, Davis Medical Center, Sacramento, USA
    Cancer Biother Radiopharm 23:783-96. 2008
    ..Further, these SHALs can be used to transport and residualize cytotoxic agents near critical sites inside these malignant cells...
  15. ncbi request reprint Pharmacokinetic characterization in xenografted mice of a series of first-generation mimics for HLA-DR antibody, Lym-1, as carrier molecules to image and treat lymphoma
    Gerald L DeNardo
    University of California Davis Cancer Center, Sacramento, California, USA
    J Nucl Med 48:1338-47. 2007
    ....
  16. ncbi request reprint High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human
    Carol M Richman
    University of California Davis, Sacramento, California 95817, USA
    Clin Cancer Res 11:5920-7. 2005
    ..In these phase I studies, paclitaxel was combined with radioimmunotherapy in patients with metastatic hormone-refractory prostate cancer or advanced breast cancer...
  17. ncbi request reprint Comparison of normal tissue pharmacokinetics with 111In/90Y monoclonal antibody m170 for breast and prostate cancer
    Joerg Lehmann
    Department of Radiation Oncology, University of California Davis School of Medicine, Sacramento, CA, USA
    Int J Radiat Oncol Biol Phys 66:1192-8. 2006
    ..This study investigated the absorbed radiation dose in normal tissues for prostate cancer patients in comparison to breast cancer patients for 2 RPs using the monoclonal antibody (MAb) m170...
  18. ncbi request reprint Development of tumor targeting anti-MUC-1 multimer: effects of di-scFv unpaired cysteine location on PEGylation and tumor binding
    Cheng Yi Xiong
    Department of Internal Medicine, Division of Hematology Oncology, Section of Radiodiagnosis and Therapy, University of California Davis Cancer Center 1508 Alhambra Boulevard, Sacramento, CA 95816, USA
    Protein Eng Des Sel 19:359-67. 2006
    ....
  19. ncbi request reprint Recombinant expression of the beta-subunit of HLA-DR10 for the selection of novel lymphoma targeting molecules
    Huguette Albrecht
    Cancer Center, University of California, Davis Medical Center, Sacramento, CA 95816, USA
    Cancer Biother Radiopharm 22:531-42. 2007
    ..Therefore, this recombinant protein can be used as a surrogate for native heterodimeric HLA DR10 for the in vitro selection of SHALs and related targeting molecules...
  20. ncbi request reprint Evaluation of a cathepsin-cleavable peptide linked radioimmunoconjugate of a panadenocarcinoma MAb, m170, in mice and patients
    Gerald L DeNardo
    Department of Internal Medicine, University of California Davis, School of Medicine, Sacramento, CA, USA
    Cancer Biother Radiopharm 19:85-92. 2004
    ....
  21. ncbi request reprint Characterization of site-specific ScFv PEGylation for tumor-targeting pharmaceuticals
    Arutselvan Natarajan
    University of California Davis Medical Center, Sacramento, California 95816, USA
    Bioconjug Chem 16:113-21. 2005
    ..ScFv-c conjugation to form PEG-(scFv-c)2 reached greatest efficiency at 45%, and its purified form demonstrated greater binding than the corresponding scFv-c...
  22. ncbi request reprint Combined modality radioimmunotherapy. Promise and peril
    Patricia A Burke
    Department of Internal Medicine, Division of Hematology and Oncology, Section of Radiodiagnosis and Therapy, University of California, Davis Medical Center, Sacramento, California 95816, USA
    Cancer 94:1320-31. 2002
    ..Thus, synergistic or combined modality radioimmunotherapy (CMRIT) agents are needed to increase radiosensitivity for therapeutic enhancement without additive toxicity...
  23. ncbi request reprint Production of soluble ScFvs with C-terminal-free thiol for site-specific conjugation or stable dimeric ScFvs on demand
    Huguette Albrecht
    Radiodiagnosis and Therapy, Molecular Cancer Institute, University of California Davis Medical Center, Sacramento, California 95816, USA
    Bioconjug Chem 15:16-26. 2004
    ..coli, either as stable scFv-Cys or (scFv-Cys)2. ScFv-Cys can be used for conjugation to PEG to form bivalent PEG (scFv-Cys)2 molecules or used as (scFv-Cys)2 for increased sensitivity in IHC...
  24. pmc Halogenated benzimidazole carboxamides target integrin alpha4beta1 on T-cell and B-cell lymphomas
    Richard D Carpenter
    Department of Chemistry, University of California, Davis, Davis, California 95616, USA
    Cancer Res 70:5448-56. 2010
    ....
  25. doi request reprint Short communication: nanoparticle thermotherapy and external beam radiation therapy for human prostate cancer cells
    Joerg Lehmann
    Department of Radiation Oncology, University of California Davis School of Medicine, Sacramento, CA, USA
    Cancer Biother Radiopharm 23:265-71. 2008
    ....
  26. ncbi request reprint Selection and characterization of anti-MUC-1 scFvs intended for targeted therapy
    Michelle D Winthrop
    University of California Davis Medical Center, Sacramento, California 95816, USA
    Clin Cancer Res 9:3845S-53S. 2003
    ..The mucin MUC-1 was chosen as an antigen because it is abundantly expressed on epithelial cancers in an aberrantly glycosylated form, making it structurally and antigenically distinct from MUC-1 expressed on normal cells...
  27. pmc Systemic radiotherapy can cure lymphoma: a paradigm for other malignancies?
    Gerald L DeNardo
    Department of Internal Medicine, University of California, Davis, Sacramento, CA 95816, USA
    Cancer Biother Radiopharm 23:383-97. 2008
    ..Smaller radionuclide carriers, such as those used for pretargeted strategies, provide dose intensification. The potential of pretargeted RIT to improve patient outcomes is striking...
  28. ncbi request reprint Implantation of different malignant human cell lines in an athymic mouse does not alter success and growth rates of either xenograft
    Laird Miers
    University of California at Davis, School of Medicine, USA
    Cancer Biother Radiopharm 20:614-9. 2005
    ..Investigations were undertaken to determine the effect of two different cell-line xenografts, and prior radiation needed for one of the xenografts, on implantation success and growth rates...
  29. doi request reprint Development of TNKase-specific cleavable peptide-linked radioimmunoconjugates for radioimmunotherapy
    Arutselvan Natarajan
    Division of Hematology and Oncology, Internal Medicine, University of California Davis, 1508 Alhambra Blvd, Room 3100, Sacramento, CA 95816, USA
    Bioorg Med Chem Lett 18:4802-5. 2008
    ..The percent release of radiochelate from RIC was 50% at 24h and 85% over 7 2h in vitro. This novel ODC-linked RIC could be a potential molecule for RIT...
  30. ncbi request reprint Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts
    Patricia A Burke
    University of California at Davis, Sacramento Medical Center, Radiodiagnosis and Therapy Internal Medicine, Sacramento, California 95816, USA
    Cancer Res 62:4263-72. 2002
    ..The enhanced therapeutic synergy is of particular note, having been achieved without additional toxicity...
  31. ncbi request reprint Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6
    ROBERT T O'DONNELL
    Department of Internal Medicine, Division of Hematology and Oncology, Section of Radiodiagnosis and Therapy, University of California Davis Medical Center, Sacramento, California 95816, USA
    Prostate 50:27-37. 2002
    ..55 MBq;150 microCi) has resulted in durable responses. To make radioimmunotherapy (RIT) more effective, the radiation-enhancing drugs Taxol (paclitaxel) and Taxotere (docetaxel) were tested for synergy with 90Y-DOTA-peptide-ChL6...
  32. ncbi request reprint Thermal dosimetry predictive of efficacy of 111In-ChL6 nanoparticle AMF--induced thermoablative therapy for human breast cancer in mice
    Sally J DeNardo
    School of Medicine, University of California Davis, Sacramento, California 95816, USA
    J Nucl Med 48:437-44. 2007
    ..To evaluate the potential of this Rx, in vivo tumor targeting, efficacy, and predictive radionuclide-based heat dosimetry were studied using (111)In-ChL6 bioprobes (ChL6 is chimeric L6) in a human breast cancer xenograft model...
  33. ncbi request reprint Documentation of idiotypic cascade after Lym-1 radioimmunotherapy in a patient with non-Hodgkin's lymphoma: basis for extended survival?
    Bonnie M Bradt
    University of California Davis Medical Center, Sacramento, California 95816, USA
    Clin Cancer Res 9:4007S-12S. 2003
    ..Immunoglobulin from the patient's plasma was purified, characterized, and shown to possess the activities expected of idiotypic antibodies...
  34. ncbi request reprint Characterization of human IgG antimouse antibody in patients with B-cell malignancies
    Gerald L DeNardo
    University of California Davis Medical Center, Sacramento, California 95816, USA
    Clin Cancer Res 9:4013S-21S. 2003
    ..This study of a large number of patients with B-cell malignancies, over an extended period of time, characterized their human antimouse antibody (HAMA) seroconversion...
  35. ncbi request reprint Direct antilymphoma effects on human lymphoma cells of monotherapy and combination therapy with CD20 and HLA-DR antibodies and 90Y-labeled HLA-DR antibodies
    Gerald L DeNardo
    Department of Internal Medicine, University of California Davis Health Sciences Center, Sacramento, California, USA
    Clin Cancer Res 11:7075s-7079s. 2005
    ..Monoclonal antibodies (mAb) in combination and mAbs combined with a radionuclide (radioimmunotherapy) have both been more effective in patients than mAb monotherapy...
  36. ncbi request reprint Direct antilymphoma activity of novel, first-generation "antibody mimics" that bind HLA-DR10-positive non-Hodgkin's lymphoma cells
    Jeremy West
    Department of Internal Medicine and Radiology, University of California, Davis, Sacramento, CA 95816, USA
    Cancer Biother Radiopharm 21:645-54. 2006
    ..Because of their small size, these SHALs have potential as radionuclide carrier substitutes for Lym-1 mAb to target the HLA-DR10 NHL-related cell-surface protein...
  37. ncbi request reprint Monospecific bivalent scFv-SH: effects of linker length and location of an engineered cysteine on production, antigen binding activity and free SH accessibility
    Huguette Albrecht
    University of California Davis Medical Center, Sacramento, 95816, USA
    J Immunol Methods 310:100-16. 2006
    ..This empirical work provides a framework for the development of bispecific scFv multimers via site-specific attachment of scFv-SH and di-scFv-SH modules to a scaffold...
  38. ncbi request reprint Human antiglobulin response to foreign antibodies: therapeutic benefit?
    Gerald L DeNardo
    Hematology and Oncology, Department of Internal Medicine, University of California Davis Medical Center, 1508 Alhambra Boulevard, Room 3100, Sacramento, CA 95816, USA
    Cancer Immunol Immunother 52:309-16. 2003
    ..An induced immune cascade in these patients, including anti-idiotypic Ab (Ab2) and cytotoxic Ab1' or Ab3 probably contributed to survival. In summary, HAGA should not a priori preclude the therapeutic use of Ab for cancer...
  39. ncbi request reprint Cure of incurable lymphoma
    Gerald L DeNardo
    Radiodiagnosis and Therapy, Division of Hematology Oncology, University of California Davis Medical Center, Sacramento, CA, USA
    Int J Radiat Oncol Biol Phys 66:S46-56. 2006
    ..Predictable improvements using better drugs, strategies, and combinations with other drugs seem certain to make RIT integral to the management of patients with NHL, and likely lead to cure of currently incurable NHL...
  40. ncbi request reprint Radiometals as payloads for radioimmunotherapy for lymphoma
    Gerald L DeNardo
    Radiodiagnosis and Therapy, Division of Hematology Oncology, University of California Davis Medical Center, Sacramento, USA
    Clin Lymphoma 5:S5-10. 2004
    ..It is clear that RIT has emerged as a safe and efficient method for treatment of NHL, especially in specific settings...
  41. ncbi request reprint Radioimmunodetection and therapy of breast cancer
    Sally J DeNardo
    Department of Internal Medicine, Division of Radiodiagnosis and Therapy, University of California Davis Medical Center, Sacramento, CA 95816, USA
    Semin Nucl Med 35:143-51. 2005
    ..These strategies for detection and treatment of metastatic breast cancer should lead to notable clinical impact on management and cure of breast cancer...
  42. ncbi request reprint Recombinant antibodies: from the laboratory to the clinic
    Huguette Albrecht
    University of California Davis Medical Center, Sacramento, CA 95816, USA
    Cancer Biother Radiopharm 21:285-304. 2006
    ..Multitargeted and combination therapies are rapidly evolving for the treatment of cancer. Antibody therapeutics, costly to develop and produce, have proven beneficial in the clinic...
  43. ncbi request reprint Targeted radionuclide therapy for solid tumors: an overview
    Sally J DeNardo
    Radiodiagnosis and Therapy, Division of Hematology Oncology, University of California Davis Medical Center, Sacramento, CA, USA
    Int J Radiat Oncol Biol Phys 66:S89-95. 2006
    ..This can be readily accomplished clinically using quantitative high-resolution imaging (e.g., positron emission tomography [PET])...
  44. ncbi request reprint Radiation dosimetry for radionuclide therapy in a nonmyeloablative strategy
    Gerald L DeNardo
    Division of Hematology Oncology, University of California Davis Medical Center, Sacramento, California, USA
    Cancer Biother Radiopharm 17:107-18. 2002
    ..Marrow dosimetry can be expected to improve significantly but no method for marrow dosimetry seems likely to account for decreased bone marrow reserve...
  45. pmc In-vivo biodistribution and safety of 99mTc-LLP2A-HYNIC in canine non-Hodgkin lymphoma
    Allison L Zwingenberger
    Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California Davis, Davis, California, United States of America
    PLoS ONE 7:e34404. 2012
    ..This compound is promising in the development of targeted drug-delivery radiopharmaceuticals and may contribute to translational work in people affected by non-Hodgkin lymphoma...
  46. ncbi request reprint Rationales, evidence, and design considerations for fractionated radioimmunotherapy
    Gerald L DeNardo
    Department of Internal Medicine, Division of Hematology and Oncology, Section of Radiodiagnosis and Therapy, University of California, Davis Medical Center, Sacramento, California 95816, USA
    Cancer 94:1332-48. 2002
    ....
  47. pmc A general chemical synthesis platform for crosslinking multivalent single chain variable fragments
    Joan G Schellinger
    Chemistry Department, University of California Davis, One Shields Avenue, Davis, CA 95616, USA
    Org Biomol Chem 10:1521-6. 2012
    ....
  48. pmc Update: Turning the heat on cancer
    Gerald L DeNardo
    Cancer Center, University of California Davis Medical Center, Sacramento, 95816, USA
    Cancer Biother Radiopharm 23:671-80. 2008
    ..Importantly, hyperthermia does not damage, and may actually enhance, the immune system. Trials in patients are needed to settle the clinical role of new thermal treatment...
  49. pmc The remarkable stability of chimeric, sialic acid-derived alpha/delta-peptides in human blood plasma
    Jonel P Saludes
    Department of Chemistry, University of California, Davis, 95616, USA
    Chem Biol Drug Des 75:455-60. 2010
    ..These findings provide a viable platform for the synthesis of plasma stable, sialic acid-derived peptides that may find pharmaceutical application...
  50. doi request reprint Concepts, consequences, and implications of theranosis
    Gerald L DeNardo
    Department of Internal Medicine, University of California at Davis, Sacramento, CA, USA
    Semin Nucl Med 42:147-50. 2012
    ..Drugs that work in one individual may be ineffective or cause adverse events in others...
  51. ncbi request reprint Selecting an intervention time for intravascular enzymatic cleavage of peptide linkers to clear radioisotope from normal tissues
    Christine L Hartmann Siantar
    Glenn T Seaborg Institute, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA
    Cancer Biother Radiopharm 22:556-63. 2007
    ..This paper presents a method to predict preferred intervention times and TIs by using pharmacokinetic tracer studies carried out without intervention...
  52. ncbi request reprint Effect of antilymphoma antibody, 131I-Lym-1, on peripheral blood lymphocytes in patients with non-Hodgkin's lymphoma
    Orazio Schillaci
    Department of Biopathology and Diagnostic Imaging, University Tor Vergata, Rome, Italy
    Cancer Biother Radiopharm 22:521-30. 2007
    ....
  53. ncbi request reprint Synthesis and radiolabeling of selective high-affinity ligands designed to target non-Hodgkin's lymphoma and leukemia
    Saphon Hok
    Chemistry, Materials and Life Sciences Directorate, Lawrence Livermore National Laboratory, Livermore, California 94551, USA
    Bioconjug Chem 18:912-21. 2007
    ..Radiolabeling reactions of DOTA-SHALs, with exactly one DOTA entity per targeting SHAL molecule, yielded products with greater than 90% radiochemical purity and specific activities ranging from 97 to 150 muCi/mug...
  54. ncbi request reprint Splenic volume change and nodal tumor response in non-Hodgkin's lymphoma patients after radioimmunotherapy using radiolabeled Lym-1 antibody
    Sui Shen
    Department of Radiation Oncology, University of Alabama, Birmingham, 35294, USA
    Cancer Biother Radiopharm 20:662-70. 2005
    ..Splenomegaly is frequently found in non-Hodgkin's lymphoma (NHL) patients. This study evaluated the implications of splenic volume change in response to radioimmunotherapy (RIT) using radiolabeled Lym- 1 antibody...
  55. pmc Dynamic force spectroscopy of parallel individual Mucin1-antibody bonds
    Todd A Sulchek
    Lawrence Livermore National Laboratory, Livermore, CA 94550, USA
    Proc Natl Acad Sci U S A 102:16638-43. 2005
    ..Our approach is promising for comparison of the specific effects of molecular modifications as well as for determination of the best configuration of antibody-based multivalent targeting agents...
  56. ncbi request reprint Application of high amplitude alternating magnetic fields for heat induction of nanoparticles localized in cancer
    Robert Ivkov
    Triton BioSystems, Inc, Chelmsford, Massachusetts 01824, USA
    Clin Cancer Res 11:7093s-7103s. 2005
    ..In this study, application of high-amplitude, confined, pulsed AMF to a mouse model is explored with the goal to provide data for a concomitant efficacy study of heating i.v. injected magnetic nanoparticles...
  57. ncbi request reprint Planning time for peripheral blood stem cell infusion after high-dose targeted radionuclide therapy using dosimetry
    Sui Shen
    Department of Radiation Oncology, Wallace Tumor Institute, University of Alabama at Birmingham, 1824 6th Avenue S, Birmingham, AL 35294, USA
    J Nucl Med 46:1034-41. 2005
    ..This study proposes to plan PBSC infusion time based on noninvasive dosimetry that considers damage of PBSCs during PBSC circulation and residence in organs with high radioactivity...
  58. ncbi request reprint Impact of nodal regression on radiation dose for lymphoma patients after radioimmunotherapy
    Christine L Hartmann Siantar
    Glenn T Seaborg Institute, Lawrence Livermore National Laboratory, PO Box 808, Livermore, CA 94550, USA
    J Nucl Med 44:1322-9. 2003
    ..This article investigates the impact of nodal regression on absorbed radiation dose and applies a correction factor to account for its effect...
  59. ncbi request reprint Treatment planning for molecular targeted radionuclide therapy
    Christine Hartmann Siantar
    Glenn T Seaborg Institute, L 231, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA
    Cancer Biother Radiopharm 17:267-80. 2002
    ....
  60. ncbi request reprint Survival benefit associated with human anti-mouse antibody (HAMA) in patients with B-cell malignancies
    Ignacio Azinovic
    Department of Radiotherapy, Hospital San Jaime, Torrevieja, 03180, Alicante, Spain
    Cancer Immunol Immunother 55:1451-8. 2006
    ....